4-Hydroxy-6-propyloxan-2-one

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 内酯类
• 英文名称: 4-Hydroxy-6-propyloxan-2-one
• 化学式: C₈H₁₄O₃
• 分子量: 158.19
• InChiKey: TWSUWPLPZNCARG-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  0.9
• 重原子数：
  11
• 可旋转键数：
  2
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.88
• 拓扑面积：
  46.5
• 氢给体数：
  1
• 氢受体数：
  3

文献信息

• PYRROLO SULFONAMIDE COMPOUNDS FOR MODULATION OF ORPHAN NUCLEAR RECEPTOR RAR-RELATED ORPHAN RECEPTOR-GAMMA (ROR-GAMMA, NR1F3) ACTIVITY AND FOR THE TREATMENT OF CHRONIC INFLAMMATORY AND AUTOIMMUNE DISEASES
  申请人：Steeneck Christoph

  公开号：US20140142082A1

  公开（公告）日：2014-05-22

  The invention provides modulators for the orphan nuclear receptor RORy and methods for treating RORy mediated diseases by administrating these novel RORy modulators to a human or a mammal in need thereof. Specifically, the present invention provides pyrrolo sulfonamide compounds of Formula (1) and the enantiomers, diastereomers, tautomers, solvates and pharmaceutically acceptable salts thereof.

  该发明提供了调节孤儿核受体RORy的调节剂，并通过向需要治疗RORy介导疾病的人类或哺乳动物施用这些新型RORy调节剂的方法进行治疗。具体而言，本发明提供了化合物1的吡咯磺酰胺化合物及其对映体，异构体，互变异构体，溶剂化物和药学上可接受的盐。
• PYRIMIDINE COMPOUNDS INHIBITING THE FORMATION OF NITRIC OXIDE AND PROSTAGLANDIN E2, METHOD OF PRODUCTION THEREOF AND USE THEREOF
  申请人：Ustav Organicke Chemie A Biochemie Akademie Ved Cr, v.v.i.

  公开号：EP3195867A1

  公开（公告）日：2017-07-26

  The invention provides pyrimidine compounds of general formula (I), which reduce simultaneously the production of nitric oxide (NO) and prostaglandin E2 (PGE2). They have no negative effect on the viability of cells in concentrations decreasing the production of these factors by up to 50%; they are not cytotoxic. Furthermore, a method of preparation of the pyrimidine compounds of general formula (I), carrying 2-formamido group, a pharmaceutical composition comprising the substituted pyrimidine compounds according to the invention, and the use of these compounds for the treatment of inflammatory and cancer diseases are provided.

  本发明提供了通式（I）的嘧啶化合物，它们能同时减少一氧化氮（NO）和前列腺素 E2（PGE2）的产生。它们对细胞的存活能力没有负面影响，在减少这些因子产生达 50%的浓度下，它们没有细胞毒性。此外，本发明还提供了通式(I)嘧啶化合物的制备方法、含有 2-甲酰基的嘧啶化合物的药物组合物，以及这些化合物用于治疗炎症和癌症疾病的方法。
• LIVER TARGETED CONJUGATES
  申请人：THE PRESIDENT & FELLOWS OF HARVARD COLLEGE

  公开号：EP1948600B1

  公开（公告）日：2014-04-16
• PROCESS FOR THE PREPARATION OF DELTA LACTONES
  申请人：Isobionics B.V.

  公开号：EP1969131A1

  公开（公告）日：2008-09-17
• Compositions and methods for the treatment of cardiovascular disease
  申请人：Gjorstrup Per

  公开号：US20070254897A1

  公开（公告）日：2007-11-01

  The invention relates to methods of treating cardiovascular disease comprising administering a resolvin, lipoxin, or oxylipin compound.